Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III immunogenicity and safety study of a recombinant 9-valent HPV vaccine in Chinese females aged 9-45 years
CTR20211044Phase 3Active
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), vaginal cancer, Vulval carcinoma, cervical intraepithelial neoplasia (CIN), sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Started May 2021; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vaginal cancerVulval carcinomacervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on CTR20211044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211044.